The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)

Part of paid clinical trials in Cooperstown, New York.

Sponsor
Bassett Healthcare
Study ID
NCT07556107
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Acute Kidney Injury
  • Infection
  • Sepsis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Piperacillin + Tazobactam — DRUG
    PT Dosing (concealed): PT dosing is standard irrespective of infection severity. 4.5 gm IV loading dose over 30 min, then 4.5 g IV over 4 hr (extended infusion) 6 hrs after the loading dose, and then q 8 hr
  • meropenem — DRUG
    M dosing (concealed): M dosing depends on infection severity. 1 gm loading IV dose over 30 min, then 1 gm IV over 4 hr (extended infusion) q 8 hr (default dosing). Clinician has option to increase to 2 gm IV q 8 hr for severe infections and to decrease back to default dosing if previously chosen higher dosing is no longer deemed indicated.

Study Details

The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they can make better choices for their patients.

Key Dates

Start date
Jun 1, 2026
Status verified
Apr 2026
Primary completion
Jun 30, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
852 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Piperacillin/tazobactam
    Vancomycin plus piperacillin/tazobactam
  • Active Comparator: Meropenem
    Vancomycin plus meropenem

Primary Outcome Measure

Serum cystatin C (Scys) [ Time Frame: 7 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Bassett Medical CenterCooperstownNew York13326
Jennifer Victory
[email protected]
6075476965

Find similar trials in Cooperstown, NY

By research site
Bassett Medical Center· Cooperstown, NY

Related Studies